Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 9, Number 1—January 2003

Perspective

Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors

W. Michael Scheld*Comments to Author 
Author affiliation: *University of Virginia, School of Medicine, Charlottesville, Virginia, USA

Main Article

Table 1

Comparison of in vitro activitya of four fluoroquinolones against a range of pathogensb

Fluoroquinolone E. coli P. aeruginosa K. pneumoniae S. pneumoniaec S. aureusd Ref.
Ciprofloxacin
0.03
8
NR
4
0.5
12

0.125–0.5
0.25–4
0.25
1-2
0.5–1
13

0.016
8
0.06
4
0.5
14

0.016
2
0.25
2
0.5
15

0.25
4
0.06
2
1
16
Levofloxacin
NR
32
NR
2
0.25
12

0.06–<0.5
0.5–>4
0.12–0.25
1–2
0.25
13

0.03
32
0.13
2
0.25
14

0.06
4
0.25
2
0.25
15

0.12
16
0.12
1
0.5
16
Moxifloxacin
0.06
8
NR
0.25
0.06
12

0.06–1
8
0.12–0.25
0.06–0.25
0.12
13

0.008
32
0.13
0.25
0.06
14

0.06
8
0.5
0.25
0.06
15

0.5
8
0.5
0.25
0.12
16
Gatifloxacin
NR
32
NR
1.0
0.125
12

0.06
>4
0.06–0.25
0.5
0.12
13

0.016
32
0.13
1
0.13
14
0.1 8 0.12 0.5 0.12 15

aMIC90 reported.
bE. coli, Escherichia coli; P. aeruginosa, Pseudomonas aeruginosa; K. pneumoniae, Klebsiella pneumoniae; S. pneumoniae, Streptococcus pneumoniae; S. aureus, Staphylococcus aureus; NR, not reported.
cPenicillin-susceptible S. pneumoniae, except in the case of Reference 12, which did not specify.
dMethicillin-susceptible S. aureus, except in the case of Reference 12, which did not specify.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO